Alglucosidase alfa (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Alglucosidase alfa" in English language version.

refsWebsite

Global rank English rank

10web.archive.org

1^st place

4fda.gov

447^th place

338^th place

3nih.gov

4^th place

1europa.eu

68^th place

117^th place

1ama-assn.org

3,257^th place

3,398^th place

1doi.org

2^nd place

1wsj.com

79^th place

65^th place

1magellanrx.com

low place

ama-assn.org

American Medical Association (USAN). "Alglucosidase alfa". Statement on a Nonproprietary Name Adopted by the USAN Council. Archived from the original (Microsoft Word) on 12 February 2012. Retrieved 18 December 2007.

doi.org

Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. (January 2007). "Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease". Neurology. 68 (2): 99–109. doi:10.1212/01.wnl.0000251268.41188.04. PMID 17151339.

europa.eu

ema.europa.eu

"Myozyme EPAR". European Medicines Agency. 14 February 2001. Archived from the original on 28 December 2021. Retrieved 15 May 2024.

fda.gov

"FDA Approves First Treatment for Pompe Disease". FDA. 28 April 2006. Archived from the original on 19 May 2006. Retrieved 7 July 2008.
"FDA expands approval of drug to treat Pompe disease to patients of all ages; removes risk mitigation strategy requirements". FDA. 14 August 2014. Archived from the original on 3 August 2014.

accessdata.fda.gov

"Drug Approval Package: Myozyme (Alglucosidase Alfa) NDA #125141". U.S. Food and Drug Administration. Archived from the original on 12 April 2021. Retrieved 14 August 2020.
"Drug Approval Package: Lumizyme (alglucosidase alfa) NDA #125291". U.S. Food and Drug Administration. Archived from the original on 30 November 2020. Retrieved 14 August 2020.
- Lay summary in: "Center for Drug Evaluation and Research: Application Number: 125291: Summary Review" (PDF). Food and Drug Administration.

magellanrx.com

www1.magellanrx.com

"Magellan Rx Management Medical Pharmacy Trend Report" (PDF) (7th ed.). 2016. Archived from the original (PDF) on 29 March 2019.

nih.gov

dailymed.nlm.nih.gov

"Lumizyme- alglucosidase alfa injection, powder, for solution". DailyMed. 22 February 2020. Archived from the original on 25 March 2021. Retrieved 14 August 2020.
"Myozyme (alglucosidase alfa) Injectable for intravenous infusion Initial U.S. Approval: 2006". DailyMed. Archived from the original on 18 December 2022. Retrieved 18 December 2022.

pubmed.ncbi.nlm.nih.gov

Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. (January 2007). "Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease". Neurology. 68 (2): 99–109. doi:10.1212/01.wnl.0000251268.41188.04. PMID 17151339.

web.archive.org

"Lumizyme- alglucosidase alfa injection, powder, for solution". DailyMed. 22 February 2020. Archived from the original on 25 March 2021. Retrieved 14 August 2020.
"FDA Approves First Treatment for Pompe Disease". FDA. 28 April 2006. Archived from the original on 19 May 2006. Retrieved 7 July 2008.
"Myozyme (alglucosidase alfa) Injectable for intravenous infusion Initial U.S. Approval: 2006". DailyMed. Archived from the original on 18 December 2022. Retrieved 18 December 2022.
"Myozyme EPAR". European Medicines Agency. 14 February 2001. Archived from the original on 28 December 2021. Retrieved 15 May 2024.
American Medical Association (USAN). "Alglucosidase alfa". Statement on a Nonproprietary Name Adopted by the USAN Council. Archived from the original (Microsoft Word) on 12 February 2012. Retrieved 18 December 2007.
"Drug Approval Package: Myozyme (Alglucosidase Alfa) NDA #125141". U.S. Food and Drug Administration. Archived from the original on 12 April 2021. Retrieved 14 August 2020.
"Drug Approval Package: Lumizyme (alglucosidase alfa) NDA #125291". U.S. Food and Drug Administration. Archived from the original on 30 November 2020. Retrieved 14 August 2020.
- Lay summary in: "Center for Drug Evaluation and Research: Application Number: 125291: Summary Review" (PDF). Food and Drug Administration.
- "FDA expands approval of drug to treat Pompe disease to patients of all ages; removes risk mitigation strategy requirements". FDA. 14 August 2014. Archived from the original on 3 August 2014.
- Anand G (18 September 2007). "As Costs Rise, New Medicines Face Pushback". The Wall Street Journal. Archived from the original on 21 April 2019. Retrieved 7 July 2008.
- "Magellan Rx Management Medical Pharmacy Trend Report" (PDF) (7th ed.). 2016. Archived from the original (PDF) on 29 March 2019.

wsj.com

Anand G (18 September 2007). "As Costs Rise, New Medicines Face Pushback". The Wall Street Journal. Archived from the original on 21 April 2019. Retrieved 7 July 2008.